Skip to content

Effect of Guanxindanshen Dropping Pills on Quality of Life and Cardiovascular Prognosis of Patients with Depression or Anxiety after PCI for Coronary Heart Disease

Effect of Guanxindanshen Dropping Pills on Quality of Life and Cardiovascular Prognosis of Patients with Depression or Anxiety after PCI for Coronary Heart Disease

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023457
Enrollment
Unknown
Registered
2019-05-28
Start date
2017-09-14
Completion date
Unknown
Last updated
2019-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression or Anxiety after PCI for CHD

Interventions

Sponsors

Xiyuan Hospital, CACMS
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Voluntarily participate in the trial and sign the ICF; 2) To meet the diagnostic criteria of CHD and complete PCI; 3) PHQ-9 score 5-14, or GAD-7 score 5-14; 4) Aged 18-75 years old, male or female; 5) Be able to cooperate with examination and treatment.

Exclusion criteria

Exclusion criteria: 1) wicked liquid condition; 2) Unalleviated angina attack or NYHA cardiac function grade IV; 3) electrolyte disorder, acid-base imbalance; 4) Complicated with pulmonary, liver, kidney, hematopoietic system, immune system and other serious primary diseases and dysfunction; 5) Organic mental disorders, depression caused by other mental disorders such as schizophrenia or somatic diseases etc.; 6) Bipolar disorder, rapid circulatory seizures; 7) History of epilepsy; 8) Alcohol or drug abuse and drug addicts within one year; 9) Other antidepressants and antianxiety drugs were taken within four weeks before the trial; 10) Pregnant or lactating women or planned pregnancies; 11) Those who have participated in clinical trials of other drugs within 3 months; 12) Researchers do not consider it appropriate to participate in clinical trials; 13) Suicide-prone patients.

Design outcomes

Primary

MeasureTime frame
PHQ-9 scale;GAD-7 scale;SAQ;

Secondary

MeasureTime frame
SF-12 scale;Initial time and incident rate of MACE;

Countries

China

Contacts

Public ContactChen Keji

Xiyuan Hospital, CACMS

fucgbs@163.com+86 010 62835651

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026